CRISPR Therapeutics (CRSP) Projected to Post Quarterly Earnings on Monday

Key Points

• Q1 2026 results due before market open Monday, May 11: analysts expect EPS of ($1.2227) and revenue of $6.064 million, with an earnings call scheduled for May 14 at 4:00 PM ET.
• Recent miss and cautious outlook: CRISPR reported ($1.37) EPS on Feb. 13 vs. ($1.15) expected and revenue down 97.8% YoY to $0.86M; analysts forecast ~-$5 EPS for the current fiscal year and the Street has a "Moderate Buy" consensus with a $64.53 price target.
• Insider selling amid large institutional stakes: insiders sold 51,828 shares (~$2.58M) over the last 90 days including CEO sales (insiders own 4.10%), while institutions own about 69.2% of the stock (notable positions: ARK, GSK, State Street).

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) is expected to be issuing its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($1.2227) per share and revenue of $6.0640 million for the quarter. Parties are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:00 PM ET.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings results on Friday, February 13th. The company reported ($1.37) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.22). CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The company had revenue of $0.86 million during the quarter, compared to analyst estimates of $4.72 million. During the same period in the prior year, the business posted ($1.01) EPS. CRISPR Therapeutics's revenue for the quarter was down 97.8% compared to the same quarter last year. On average, analysts expect CRISPR Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

CRISPR Therapeutics Stock Performance

NASDAQ:CRSP opened at $51.63 on Monday. The stock has a market cap of $4.98 billion, a PE ratio of -7.92 and a beta of 1.74. CRISPR Therapeutics has a one year low of $33.03 and a one year high of $78.48. The stock has a 50 day moving average price of $52.43 and a 200 day moving average price of $54.74.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on CRSP shares. Piper Sandler reiterated an "overweight" rating and issued a $110.00 price objective (up from $105.00) on shares of CRISPR Therapeutics in a research report on Tuesday, March 17th. Chardan Capital increased their price objective on CRISPR Therapeutics from $74.00 to $76.00 and gave the stock a "buy" rating in a research report on Saturday, February 14th. Truist Financial upgraded CRISPR Therapeutics to a "strong-buy" rating in a research report on Wednesday, March 25th. TD Cowen increased their price objective on CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a "hold" rating in a research report on Friday, February 13th. Finally, Morgan Stanley reiterated an "underweight" rating and issued a $33.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, February 17th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $64.53.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 10,349 shares of the firm's stock in a transaction on Monday, March 16th. The stock was sold at an average price of $48.26, for a total transaction of $499,442.74. Following the completion of the transaction, the chief executive officer directly owned 245,834 shares in the company, valued at $11,863,948.84. This trade represents a 4.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Naimish Patel sold 3,150 shares of the firm's stock in a transaction on Monday, March 16th. The stock was sold at an average price of $48.26, for a total value of $152,019.00. Following the transaction, the insider owned 13,143 shares of the company's stock, valued at approximately $634,281.18. This represents a 19.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 51,828 shares of company stock worth $2,578,097 over the last ninety days. Company insiders own 4.10% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. GSK plc purchased a new position in CRISPR Therapeutics in the fourth quarter valued at $168,890,000. Orbis Allan Gray Ltd boosted its holdings in CRISPR Therapeutics by 76.9% in the second quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company's stock valued at $134,467,000 after purchasing an additional 1,201,600 shares during the period. State Street Corp boosted its holdings in CRISPR Therapeutics by 35.6% in the second quarter. State Street Corp now owns 3,270,596 shares of the company's stock valued at $159,082,000 after purchasing an additional 859,334 shares during the period. ARK Investment Management LLC boosted its holdings in CRISPR Therapeutics by 7.5% in the fourth quarter. ARK Investment Management LLC now owns 10,522,057 shares of the company's stock valued at $551,777,000 after purchasing an additional 735,084 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in CRISPR Therapeutics in the fourth quarter valued at $7,808,000. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.